Aktie A2AC4K EDITAS MEDICINE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Editas Medicine, Inc.

Aktien

A2AC4K

US28106W1036

EDIT

Realtime-Estimate Cboe BZX
Andere Börsenplätze
 17:40:00 28.06.2024 		% 5 Tage % 1. Jan.
4.65 USD -1.90% Intraday Chart für Editas Medicine, Inc. -9.10% -54.15%
14.06. Editas Medicine gibt an, dass die potenzielle Behandlung der Sichelzellenkrankheit durch Gen-Editierung in einer Phase 1/2-Studie gut vertragen wurde MT
14.06. Editas Medicine, Inc. meldet neue Daten zur Sicherheit und Wirksamkeit von Reni-cel bei 18 Patienten mit Sichelzellenanämie, die auf dem Jahreskongress der European Hematology Association vorgestellt wurden CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Editas Medicine Reports New Safety And Efficacy Data From The RUBY Trial Of Reni-Cel In 18 Patients With Sickle Cell Disease, Presented At The European Hematology Association Annual Congress
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
Editas Medicine, Inc. Reports New Safety and Efficacy Data from the Rubber Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association Annual Congress
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
Editas Medicine Announces New Safety and Efficacy Data from the Edithal Trial of Reni-Cel in 7 Patients with Transfusion-Dependent Beta Thalassemia, Presented At the European Hematology Association Annual Congress
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
Editas Medicine Preclinical Data Highlights Advancement Of In Vivo Gene Editing Medicine Technologies at The American Society Of Gene And Cell Therapy Annual Meeting
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas: Q1 Earnings Snapshot
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Editas Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine : April 2024 Corporate Presentation
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2AC4K Aktie
  4. Nachrichten Editas Medicine, Inc.
  5. Andere Sprachen